Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
ApexOnco Front Page
Recent articles
The company drops the anti-CD19 x 4-1BB project englumafusp alfa.
The group has approval for Amtagvi, but now faces the prospect of a solo launch.
Approval on the basis of Flaura2 is part of a double success for Astra's Tagrisso, which has also scored in Laura.
GSK’s Zejula win is the latest chapter in a long and convoluted history of PARP inhibition.
Lifileucel heads up the list of upcoming US FDA catalysts.
Private company trial initiations stand out in the latest week’s disclosures.
The biotech gives up on the exon 20 market, and says Tagrisso’s initial setting is no longer meaningful in the west.